Radiopharm Theranostics (ASX:RAD) to Host Webinar on Pivalate and Relapsed Brain Metastases Detection

2 min read | September 15, 2025 12:33 PM AEST | By Sonal Goyal

Google News:

Radiopharm Theranostics (ASX:RAD) to Host Webinar on Pivalate and Relapsed Brain Metastases Detection — Image source: Company Update

Recent News

3 Best ASX Dividend Stocks Supported by Strong Margins

Electro Optic Systems (ASX:EOS): Are Defence Wins Fueling a Bigger Gro...

Why More Australians Are Rethinking Term Deposits As Rates Pause

ImpediMed (ASX:IPD): Why Has This Healthcare Stock Suddenly Grabbed At...

Make Kalkine Media
My Trusted Source

Highlights

Radiopharm Theranostics will host a key opinion leader webinar on 25 September at 10:30am AEST.

The webinar will focus on Pivalate (18F-FPIA) and detection of relapsed brain metastases from solid tumors.

The webinar will also cover Pivalate’s development path, regulatory outlook and commercial potential.

Speakers include Dr Dimitris Voliotis, Dr Ramji Rajendran, and Riccardo Canevari.

Radiopharm Theranostics (ASX:RAD), a developer of radiopharmaceutical products for diagnostic and therapeutic applications, is set to host a key opinion leader webinar on 25 September at 10:30am AEST. The session will focus on Pivalate (18F-FPIA) and its use in detecting relapsed brain metastases from solid tumors.

Speakers include Dr Dimitris Voliotis (Chief Medical Officer of RAD), Dr Ramji Rajendran, and Riccardo Canevari (MD and CEO of RAD)

The webinar will explore the current challenges and unmet needs in radiographic detection of relapsed brain metastases and implications for therapeutic approaches, provide background on Pivalate as a novel imaging agent, and outline its path to approval and commercial potential. A Q&A session will follow.

About Pivalate

F18-Pivalate is a novel radiotracer designed for detecting, characterising, and monitoring progression of glioblastoma and relapsed brain metastases. It targets fatty acid synthase, which is selectively overexpressed in tumors but not in normal brain cells, enabling a potentially transformational approach in the imaging and monitoring of brain metastases.

Unlike FDG PET and MRI, which face challenges in distinguishing necrosis, inflammation, and recurrence, Pivalate offers a more precise and reliable tool for clinicians, highlighted the company update.

Data source: Company update

RAD shares traded at AUD 0.031 per share at the time of writing on 15 September 2025.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.